The role of LILRB3-mediated immunomodulation on myeloid cells and exploration of new combination therapy for chronic inflammation and cancer

Research Project

Project/Area Number	24K18478
Research Category	Grant-in-Aid for Early-Career Scientists
Allocation Type	Multi-year Fund
Review Section	Basic Section 50010:Tumor biology-related
Research Institution	Tohoku University
Principal Investigator	謝玉てい東北大学, 加齢医学研究所, 学術研究員 (70939280)
Project Period (FY)	2024-04-01 – 2027-03-31
Project Status	Granted (Fiscal Year 2024)
Budget Amount *help	¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000) Fiscal Year 2026: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2025: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000) Fiscal Year 2024: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Keywords	LILRB3 / integrin / HMGN1
Outline of Research at the Start	This study aims to investigate the pathways and factors involved in LILRB3-mediated immunosuppression in tumor microenvironment (TME) using the myeloid cells and mice models, and explore the possibility of HMGN1 in restoring the immunosuppression induced by LILRB3 in the myeloid cells.